Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 1, 2007, Pages 41-47

  Stamer, U M ^a   Musshoff, F ^a   Kobilay, M ^a   Madea, B ^a   Hoeft, A ^a   Stuber, F ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; TRAMADOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENANTIOMER; FEMALE; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ANALGESIA, PATIENT-CONTROLLED; ANALGESICS, OPIOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TRAMADOL; TREATMENT OUTCOME;

EID: 34250614223     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100152     Document Type: Article

References (31)

1. Phillips, K.A., Veenstra, D.L., Oren, E., Lee, J.K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).
2. Zanger, U.M., Raimundo, S. & Eichelbaum, M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn. Schmiedebergs Arch. Pharmacol. 369, 23-37 (2004).
3. Cascorbi, I. Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur. J. Clin. Invest. 33(Suppl 2): 17-22 (2003).
4. Løvlie, R., Daly, A.K., Molven, A., Idle, J.R. & Steen, V. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392, 30-34 (1996).
5. Kirchheiner, J., Sasse, J., Meineke, I., Roots, I. & Brockmoller, J. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Pharmacogenetics 13, 721-728 (2003).
6. Poulsen, L., Arendt-Nielsen, L., Brøsen, K. & Sindrup, S.H. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. 60, 636-644 (1996).
7. Stamer, U.M. et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 105, 231-238 (2003).
8. Brockmoller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C. & Muller-Oerlinghausen, B. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin. Pharmacol. Ther. 72, 438-452 (2002).
9. Kirchheiner, J. et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatr. 9, 442-473 (2004).
10. Enggaard, T.P., Poulsen, L., Arendt-Nielsen, L., Brosen, K., Ossig, J. & Sindrup, S.H. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 102, 146-150 (2006).
11. Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2221 (2005).
12. Paar, W.D., Poche, S., Gerloff, J. & Dengler, H.J. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur. J. Clin. Pharmacol. 53, 235-239 (1997).
13. Gillen, C., Haurand, M., Kobelt, D.J. & Wnendt, S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human muopioid receptor. Naunyn. Schmiedebergs Arch. Pharmacol. 362, 116-121 (2000).
14. Raffa, R.B., Friderichs, E., Reimann, W., Shank, R.P., Codd, E.E. & Vaught, J.L. Opioid and non-opioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J. Pharmacol. Exp. Ther. 260, 275-278 (1992).
15. Desmeules, J.A.M., Piguet, V., Collart, L. & Dayer, P. Contribution of monoaminergic modulation to analgesic effect of tramadol. Br. J. Clin. Pharmacol. 48, 7-12 (1996).
16. Pedersen, R.S., Damkier, P. & Brosen, K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur. J. Clin. Pharmacol. 62, 513-521 (2006).
17. Stamer, U.M., Bayerer, B., Wolf, S., Hoeft, A. & Stüber, F. Rapid and reliable method for Cytochrome P450 2D6 Genotyping. Clin. Chem. 48, 1412-1417 (2002).
18. Pang, W.W., Mok, M.S., Huang, S., Hung, C.P & Huang, M.H. Intraoperative loading attenuates nausea and vomiting of tramadol patient-controlled analgesia. Can. J. Anaesth. 47, 968-973 (2000).
19. Jellinek, H. et al. Tramadol zur postoperativen Schmerztherapie. Patientenkontrollierte Analgesie versus kontinuierlche Infusion. Anaesthesist 39, 513-520 (1990).
20. Hackl, W., Fitzal, S., Lackner, F. & Weindlmayr-Goettel, M. Comparison of fentanyl and tramadol in pain therapy with an on-demand analgesia computer in the early postoperative phase. Anaesthesist 35, 665-671 (1986).
21. Grond, S., Meuser, T., Uragg, H., Stahlberg, H.J. & Lehmann, K.A. Serum concentrations of tramadol enantiomers during patient-controlled analgesia. Br. J. Clin. Pharmacol. 48, 254-257 (1999).
22. Lehmann, K.A., Kratzenberg, U., Schroeder-Bark, B. & Horrichs-Haermeyer, G. Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations. Clin. J. Pain 6, 212-220 (1990).
23. Laugesen, S., Enggaard, T.P., Pedersen, R.S., Sindrup, S.H. & Broesen, K. Paroxetine, a cytochrome P4502D6 inhibitor, diminishes the stereoselecctive O-demethylation and reduces the hypoalgesic effect of tramadol. Clin. Pharmacol. Ther. 77, 312-323 (2005).
24. Payne, K.A., Roelofse, J.A. & Shipton, E.A. Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4-7 years - a pilot study. Anesth. Prog. 49, 109-112 (2002).
25. Sachse, C., Brockmöller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Gen. 60, 284-295 (1997).
26. Raimundo, S. et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmaco. Ther. 76, 128-138 (2004).
27. Rieger, K. et al. High prevalence of unknown co-medication in hospitalised patients. Eur. J. Clin. Pharmacol. 50, 363-368 (2004).
28. Samer, C.F., Piguet, V., Dayer, P. & Desmeules, J.A. Genetic polymorphism and drug interactions: their importance in the treatment of pain. Can. J. Anaesth. 52, 806-821 (2005).
29. Borges, S. et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74 (2006).
30. Musshoff, F., Madea, B., Stüber, F. & Stamer, U.M. Enantiomeric determination of tramadol and O-desmehyltramadol by liquid chromatography-mass spectrometry and application to patients receiving tramadol. J. Anal. Toxicol. 30, 463-467 (2006).
31. Steen, V.M. et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5, 215-223 (1995).